SingleMetabolic / GLP-1

Semaglutide 20mg

Potent GLP-1 receptor agonist studied for appetite regulation, delayed gastric emptying, and sustained cardiometabolic modulation.

Mechanism

Semaglutide acts as a selective GLP-1 receptor agonist, enhancing glucose-dependent insulin secretion, suppressing glucagon release, and stimulating central satiety pathways to delay gastric emptying.

Dosing

Standard research protocols initiate administration at 0.25 mg once weekly for the initial 4-week titration phase.

Reconstitution

Reconstituting a 20 mg vial with 3.0 mL of bacteriostatic water yields an approximate working concentration of 6.67 mg/mL.

Storage

Store the lyophilized peptide frozen at −20 °C, and keep the reconstituted solution refrigerated between 2 °C and 8 °C for up to 4 weeks away from light.

Mix & measure Semaglutide 20mg

Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.

Mix & measure Semaglutide 20mg

Vial strength → BAC water → target dose

Vial strength

BAC water

Target dose

Concentration6.67mg/mL

Draw volume0.037mL

On the syringe3.75units

Total doses in vial: 80.0

100u80u60u40u20u0

U-100 syringe: 100 units = 1 mL

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →

Dosing Chart

Phase / Day(s)	Dose & Frequency	Volume (U-100 units / mL)
Weeks 1–4	0.25 mg weekly	3.75 units (0.0375 mL)
Weeks 5–8	0.5 mg weekly	7.5 units (0.075 mL)
Weeks 9–12	1.0 mg weekly	15 units (0.15 mL)
Weeks 13–16	1.7 mg weekly	25.5 units (0.255 mL)
Weeks 17+ (Maintenance)	2.4 mg weekly	36 units (0.36 mL)

Reconstitution Steps

1
Aseptically draw 3.0 mL of bacteriostatic water into a clean preparation syringe.
2
Introduce the diluent gently against the inner wall of the 20 mg peptide vial to avoid excessive agitation or foaming.
3
Swirl or rotate the vial smoothly until the lyophilized cake is fully dissolved, avoiding vigorous shaking.
4
Document the reconstitution date on the vial label and place it immediately in a 2–8 °C refrigerated environment protected from light.

Supplies Needed

Peptide Vial

20 mg lyophilized Semaglutide container for laboratory research

Insulin Syringes (U-100)

1 mL U-100 syringes used to measure precise weekly micro-volumes

Bacteriostatic Water

3.0 mL sterile diluent per vial for reconstitution and stable multi-dose use

Alcohol Swabs

Sterilizing the vial rubber stopper and designated injection site before each draw

Why researchers study it

Weight management and adiposity reduction

Appetite suppression and central satiety control

Glucose-dependent glycemic and HbA1c regulation

Cardiometabolic risk factor modulation

These describe what is being studied, not proven benefits, approved uses, or promised results.

Overview

Semaglutide is an extensively characterized synthetic peptide analog designed to mimic the action of endogenous glucagon-like peptide-1 (GLP-1). Engineered with key structural modifications that extend its biological half-life to approximately one week, it exhibits robust resistance to rapid enzymatic degradation by dipeptidyl peptidase-4 (DPP-4). In pre-clinical and clinical investigations, semaglutide serves as a cornerstone model for exploring long-acting incretin mimetics in metabolic disease. Research interest surrounding semaglutide focuses prominently on its dual effects on energy balance and glucose homeostasis. By selectively targeting GLP-1 receptors across peripheral organs and central nervous system centers governing hunger, the compound modulates central satiety processing while slowing gastric motility. These physiological interventions lead to a consistent reduction in caloric consumption and substantial improvements in glycemic indicators in metabolic research models. Due to its pharmacokinetic profile and potent physiological potency, research designs implement a systematic dosage escalation. Gradual upward titration allows physiological systems to adapt, attenuating undesirable gastrointestinal disturbances often observed with rapid exposure to GLP-1 pathway stimulation, making strict titration adherence essential in laboratory environments.

References

1.Wilding et al., New England Journal of Medicine, 2021 — Once-weekly semaglutide 2.4 mg in adults with overweight or obesity (STEP 1)
2.Davies et al., The Lancet, 2021 — Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2)
3.O'Neil et al., The Lancet, 2018 — Phase 2 dose-finding and tolerability evaluation of semaglutide in type 2 diabetes
4.Drucker, Nature Reviews Endocrinology, 2024 — GLP-1 receptor agonists for obesity and diabetes clinical landscape
5.GenScript, Technical Bulletin, 2023 — Guidelines for peptide storage, reconstitution, and stability handling